The Wnt signaling pathway is one of the major developmental signaling pathways regulating important processes such as cell proliferation, polarity, and specification of cell fate (1, 2) . It consists of a large array of signaling molecules that allow convergence and divergence of signaling events. Dvl, 1 Axin, and Ccd1 are three known DIX domain-containing proteins that play important roles in the Wnt signaling pathway (3) (4) (5) .
In this pathway, Dvl is an intracellular protein and transduces signals from the Wnt receptor frizzled to Axin through heterodimer formation via the DIX domain (6) . Axin forms a multimeric protein complex with, in addition to Dvl, adenomatous polyposis coli, glycogen synthase kinase-3␤, and ␤-catenin (7) (8) (9) . This complex enhances phosphorylation by glycogen synthase kinase-3␤ and subsequent ubiquitination and degradation of ␤-catenin (10, 11) . Ccd1, a recently identified protein with a DIX domain, is a positive regulator in the Wnt signaling pathway during zebrafish neural patterning (5) . It functions downstream of the Wnt receptor and upstream of Axin. Ccd1 can activate T-cell factors-dependent transcription in a transient transfection reporter assay. Cotransfection of the fulllength Ccd1 resulted in TOPtkLuciferase reporter transcriptional activation comparable with the activation by Dvl expression. Overexpression of Ccd1 in zebrafish embryos caused a reduction in the size of the eyes and forebrain, which is similar to the phenotype of excessive activation of Wnt signaling by overexpression of Wnt8 or its receptor in zebrafish. Ccd1 also possesses a coiled-coil domain, deletion of which enables Ccd1 to function as a dominant-negative suppressor downstream of Wnt receptor activation. The molecular mechanism underlying how Ccd1 exerts its positive role in Wnt signaling is not clear. Immunoprecipitation analysis revealed that Ccd1 forms homodimers via its DIX domain and coiled-coil domain and heterodimeric complexes with Dvl via their DIX domains. It is likely that Ccd1 regulates the Wnt signaling through its association with Axin and Dvl or by modulating the interaction between Axin and Dvl. It is interesting that Axin and Dvl both activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SPAK) when overexpressed in a variety of cells even though they utilize different mechanisms for JNK activation (12, 13) . Axin and Dvl discriminate distinct pathways by differential domain utilizations (13) (14) (15) . In particular, Axin requires several structural aspects to activate JNK (12, 16, 17) . First, Axin possesses two separate domains for MEKK1 and MEKK4 binding. The MEKK1 or MEKK4 binding domain combines with a domain of unknown nature (domain X), DIX homodimerization domain, and the extreme C-terminal sumoylation motifs to activate JNK. In addition to its well established role in Wnt signaling, Dvl also exerts a critical role in the generation of epithelial planar polarity in Drosophila, which depends on its ability to activate JNK (13) . Although MEKK1/4 play essential roles in Axin-mediated JNK activation (12, 17) , Dvl instead seems to form a complex with the small GTPase Rac via its C-terminal DEP domain upon Wnt/Fz signaling (18) and activates MKK7 in the Dvl/JNK pathway (19) .
An intriguing property of Axin in JNK activation is that its conformation for MEKK1 binding is highly regulated. Upon binding to Axin, the Wnt signaling components glycogen synthase kinase-3␤ and casein kinase I␣/⑀ inhibit Axin-mediated JNK activation by preventing MEKK1 binding to Axin (14, 20) . It should be noted here that glycogen synthase kinase-3␤ and casein kinase I␣/⑀ both bind to domains outside the MEKK1 binding site, underscoring involvement of conformational changes in differential Axin complex formations. We found previously that Axin-mediated JNK activation is antagonized by Dvl heterodimer formation through its DIX domains (21) . Dvl-DIX and Dvl-⌬DEP proteins, both of which contain the DIX domain and are deficient for JNK activation, can attenuate Axin-induced JNK activation by abolishing Axin homodimerization. In the present study, we asked whether Ccd1, the novel DIX protein that plays a positive role in Wnt signaling, could also modulate JNK activation by Axin as well as Dvl.
We have generated a full-length human Ccd1 protein expression construct using the KIAA1735 clone and a series of deletion mutants. It was revealed here that Ccd1 inhibited JNK activation by Axin and Dvl. Although DIX domains are sufficient for Dvl and Ccd1 to form a dimer, the coiled-coil domain of Ccd1 is also required for its inhibition of JNK activation by Dvl. Interestingly, Ccd1, Dvl, and Rac form a ternary complex when coexpressed in the cell, suggesting that Ccd1⅐Dvl in the complex prevented Rac from being activated or activating downstream effectors. We unexpectedly found that Axin utilizes a novel domain rather than its DIX domain to interact with Ccd1, pointing to diverse interaction patterns among DIX proteins. Moreover, we found that Ccd1 binding to Axin prevented MEKK1 binding to the Axin complex and that Ccd1 itself formed a complex with MEKK4 and rendered it unable to contact Axin directly. Taken together, our results demonstrate that Ccd1 inhibits Axin-mediated JNK activation by simultaneously competing against MEKK1 binding and sequestration of MEKK4.
EXPERIMENTAL PROCEDURES
Cell Culture-Human embryonic kidney (HEK)293T cells were maintained in RPMI 1640 medium as described previously (12) . Mouse embryonic MEKK1
Ϫ/Ϫ fibroblast cells were a gift from Dr. M. Karin (University of California San Diego), which were generated as described previously (22) and were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 IU penicillin, 100 g/ml streptomycin, and 2 mM glutamine.
Construction of Plasmids-The human full-length Ccd1 cDNA was released from a KIAA1735 cDNA clone generously provided by Kazusa DNA Research Institute, Japan. It was Myc-, HA-, or FLAG-tagged at its N terminus, which was made possible by introducing an NdeI restriction site into the start codon by PCR amplification of the 5Ј-fragment. The tagged Ccd1 cDNA was then cloned into the mammalian expression vector pCMV5. Different deletion mutants of Ccd1 were constructed using either PCR or convenient restriction enzyme sites. For Ccd1⌬N, the N terminus of wild-type Ccd1 was deleted at the EcoRV site and fused in-frame to the HA or Myc tag. Ccd1⌬DIX was constructed by PCR using primers 5Ј-catatgggagggacgcaagtcaaatgc-3Ј (forward) and 5Ј-ttagtgagccaagaggacatctttg-3Ј (reverse). To construct Ccd1⌬CC, the 5Ј-terminal fragment was obtained by BamHI digestion followed by blunt end reaction with Klenow; and the 3Ј-terminal fragment was generated by PCR using primers 5Ј-catatgcgccttcttcagcagcaccag-3Ј and 5Ј-ttaattctctccatggtcttcttc-3Ј. Axin deletion mutant D1 was generated as described previously (12) . D2 was created from a fragment by PCR using primers 5Ј-tattcaccgtctagaggctgtcc-3Ј and 5Ј-gggctatgtgggatcttggatgaaaag-3Ј. D3 was constructed by replacing the SpeI/BamHI C-terminal portion of wild-type Axin with a PCR-generated fragment. The oligonucleotides for PCR were 5Ј-tattcaccgtctagaggctgtcc-3Ј and 5Ј-actagttttaccaccaaaggg-3Ј. Expression plasmids for wild-type mouse HA-Axin, Myc-Axin, FLAG-JNK1, HA-Dvl2, Myc-Dvl2, HA-Dvl⌬DIX, HA-Dvl⌬PDZ, HA-MEKK1C, HA-MEKK4C, and HA-MEKK4KM were generated as described previously (12, 17, 21) . The dominant-negative form of Rac HA-RacN17 was a kind gift from Dr. E. Manser (IMCB, Singapore). MEKK4-specific siRNA expression plasmid pSUPER-MEKK4 was constructed following the instructions of the manufacturer.
Transient Transfection, Coimmunoprecipitation, and Western Blotting-Transfection was performed in 60-mm dishes using Dosper Liposomal Transfection Reagent (Roche Applied Science) according to the manufacturer's instructions. The total amount of transfected DNA was adjusted with the respective empty where necessary. Cells were harvested at 40 h post-transfection and lysed in a lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM sodium orthovanadate, 1 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride), sonicated 10 times for 1 s each, and centrifuged at 13,000 rpm for 30 min at 4°C. HA-or Myc-tagged proteins or MEKK proteins were immunoprecipitated from the cell lysate with anti-HA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-Myc (9E10) (Santa Cruz Biotechnology, Inc.), anti-MEKK1 (Santa Cruz Biotechnology, Inc.), anti-MEKK4 (Abgent) antibodies and protein A/G Plus-agarose beads (Santa Cruz Biotechnology, Inc.). After separation on SDS-polyacrylamide gels cells were electrotransferred to polyvinylidene difluoride membrane (Roche Diagnostics), and immunoprecipitates or total cell lysates were analyzed by Western blotting as described previously (12) .
Immunokinase Assays-FLAG-tagged JNK1 was immunoprecipitated using mouse monoclonal anti-FLAG M2 beads (Sigma). JNK activity was determined as described previously using 1 g of GST-cJun-(1-79) (Stratagene) as substrate, followed by Western blotting using phospho-c-Jun antibody (Cell Signaling, Inc.) to examine the phosphorylation of c-Jun as described previously (12) .
RNA Interference-The human Ccd1-specific 19-mer nucleotide 5Ј-GGATGCCTTGCAGCAGAG-3Ј was inserted into the pSUPER vector according to the instructions of the manufacturer. To test for the efficiency of pSUPER-Ccd1, cells were cotransfected with 1, 2, or 5 g of pSUPER-Ccd1 and 0.5 g of HA-Ccd1 plus pEGFP-C2 (0.3 g) as a control for transfection efficiency. After 40 h of additional culture, cells were lysed, and the expression of Ccd1 was analyzed by immunoblotting using anti-HA. The plasmid pSUPER-MEKK4 was described previously (17) .
AP1-Luciferase Reporter Gene Assay-HEK293T cells were transfected with 0.1 g of p36-AP1-Luc together with 2 g of pSUPER vector or pSUPER-Ccd1 using DOSPER (Roche Applied Science) according to the manufacturer's instructions. The p36-AP1-Luc reporter and luciferase activity assays were as previously described (23) . Data are presented as the means from three separate experiments performed in triplicate.
Generation of Anti-Ccd1 and Anti-Axin Polyclonal Antibodies-Female New Zealand White rabbits were immunized separately with 1 mg of GST-fused Axin fragment (amino acids 348 -500) and Ccd1 fragment (amino acids 22-152) in phosphate-buffered saline with complete Freund's adjuvant. Three weeks later, the rabbits were boosted with the same proteins with incomplete Freund's adjuvant every 2 weeks for a total of three times. The polyclonal antibodies were affinity purified and characterized as described previously (24) .
RESULTS

Ccd1
Inhibits JNK Activation by Axin and Dvl-We showed previously that Dvl⌬DEP inhibits JNK activation by Axin via dimerization through their DIX domains and that binding of glycogen synthase kinase-3␤ and casein kinases causes conformational changes in Axin to disallow MEKK interaction (14, 21) . The highly regulatory nature of Axin activation of JNK prompted us to test whether the newly identified DIX domain protein Ccd1 could also modulate the ability of Axin as well as Dvl to activate JNK. We first tested whether Ccd1 alone could activate JNK activity when expressed in HEK293T cells. Myctagged Ccd1 was cotransfected with FLAG-JNK1 into HEK293T cells, and immunokinase assays were carried out. Ccd1 alone had virtually no effect on JNK activity, whereas, as shown previously Axin and Dvl each robustly activated JNK (ϳ10-fold). When cotransfected, Ccd1 drastically inhibited JNK activation by Axin. Unexpectedly, Ccd1 also virtually abolished JNK activation by Dvl (Fig. 1A) . We therefore asked whether knock-down of the endogenous Ccd1 protein could enhance JNK signaling. The siRNA expressed by pSUPER-Ccd1 could effectively reduce Ccd1 expression from the pCMV-Ccd1 plasmid (Fig. 1B, lower panels) . When the pSUPER-Ccd1 was cotransfected with an AP1-luciferase reporter, the activity of the AP1-luciferase reporter was 2.2 times its basal level (Fig. 1B,  graph) . We then examined whether Ccd1-Axin complex formation could also disturb Axin homodimerization as does Dvl to inhibit Axin-mediated JNK activation. To address this, increasing amounts of Myc-Ccd1 were cotranfected with HA-and Myc-tagged Axin, and coimmunoprecipitation with anti-HA was performed. Results showed that increasing amounts of Ccd1 did not diminish the association of Myc-Axin in the HAAxin immunoprecipitates (Fig. 1C) , indicating that Ccd1 does not interfere with Axin homodimerization.
Ccd1 Inhibits JNK Activation by Dvl through Interaction between DIX Domains-To examine the mechanism by which Ccd1 attenuated Dvl activation of JNK, we first determined the structural requirements in both Dvl and Ccd1 for Ccd1 to exert its inhibitory effect on Dvl. Cells were cotransfected with FLAG-JNK1 and HA-Dvl, HA-Dvl⌬DIX, or HA-Dvl⌬PDZ in the presence or absence of Myc-Ccd1. Although Ccd1 completely inhibited JNK activation by Dvl or Dvl⌬PDZ, it did not attenuate JNK activation by Dvl⌬DIX ( Fig. 2A) , indicating that complex formation between Ccd1 and Dvl is a prerequisite for Ccd1 inhibition. In parallel, we cotransfected different Ccd1 deletion mutants with HA-Dvl and FLAG-JNK1 and performed the immunokinase assay. Results showed that although deletion of the N-terminal region containing the leucine zipper region (Ccd1⌬N) did not affect Ccd1 inhibition of JNK activation by Dvl, Ccd1⌬CC, which removed the coiled-coil domain, and Ccd1⌬DIX lacking the DIX domain lost their abilities to inhibit JNK activation by Dvl (Fig. 2B) .
Because Dvl-mediated JNK activation requires Rac, we addressed the possibility that Ccd1 could prevent the complex formation between Dvl and Rac. However, we failed to see any change in the amount of Dvl coprecipitated with Rac by increasing levels of coexpressed Ccd1 (Fig. 2C ). In addition, These results also showed that although Ccd1 could not interact directly with Rac, Ccd1, Dvl, and Rac could coexist in the same complex, indicating that Ccd1 inhibited Dvl-mediated JNK activation by forming a ternary complex of Ccd1⅐Dvl⅐Rac, in which Dvl⅐Rac is somehow blocked from further activating JNK.
Ccd1 Utilizes Both Its DIX Domain and Coiled-coil Domain to
Inhibit JNK Activation by Axin-Ccd1 is known to possess three very noticeable structural domains: a leucine zipper motif at the N terminus, a DIX domain at the C terminus which binds Dvl, and a coiled-coil domain in the middle. These three domains were deleted individually in mutants Ccd1⌬N, ⌬DIX, and ⌬CC. We first tested for any effect of these Ccd1 mutants on JNK activation by Axin in HEK293T cells. HA-Axin and FLAG-JNK1 were cotransfected with the Ccd1 deletion mutants, and an immunokinase assay was carried out. Results showed that Ccd1⌬N is as effective as the wild-type Ccd1 in JNK inhibition, indicating that the leucine zipper motif is not required for Ccd1 to inhibit JNK activation by Axin. In contrast, Ccd1⌬DIX and Ccd1⌬CC each only partially inhibited JNK activation by Axin (Fig. 3A) . These observations indicate that both the DIX and coiled-coil domains are important and that they alone are insufficient for inhibiting JNK activation by Axin. Because Axin could activate JNK through either MEKK1 or MEKK4 in normal HEK293T cells, it is possible that the DIX or coiled-coil domain alone could only disrupt one of the two means by which Axin activates JNK. To clarify this, we carried out kinase assays using MEKK1 Ϫ/Ϫ MEF cells and pSUPER-MEKK4-treated HEK293T cells. As shown in Fig. 3B , Axin activated JNK well in MEKK1
Ϫ/Ϫ MEF cells as we demonstrated previously (17) , and wild-type Ccd1 effectively attenuated JNK activation by Axin. However, the Ccd1⌬DIX mutant that partially inhibited Axin-induced JNK activity in HEK293T cells totally abolished JNK activation by Axin to an extent comparable with that by wild-type Ccd1. In MEKK1 Ϫ/Ϫ cells, Ccd1⌬CC could not diminish JNK activation by Axin, which is solely dependent on MEKK4 (Fig. 3B) . We then tested whether the same Ccd1 mutants would affect Axin-mediated JNK activation in HEK293T cells expressing MEKK4 siRNA. In these cells, Axin-mediated JNK activation was abolished by wild-type Ccd1 or Ccd1⌬CC but not ⌬DIX (Fig. 3C) . These results indicate that the coiled-coil domain of Ccd1 is responsible for the inhibition of MEKK4-mediated JNK activation by Axin, whereas the Ccd1 DIX domain prevents JNK activation by Axin through MEKK1.
A Distinct Domain but Not the DIX Domain of Axin Participates in Complex
Formation with Ccd1-We showed previously that the DIX domain of Dvl could entirely abolish JNK activation by Axin. The observation that Ccd1 DIX domain could only partially inhibit JNK activation by Axin was somewhat peculiar but suggested that Ccd1 might not interact with the DIX domain of Axin. To test this, different deletion mutants of Ccd1 were cotransfected with Axin, and coimmunoprecipitation was carried out. Ccd1⌬N and Ccd1⌬CC, but not Ccd1⌬DIX, formed a complex with Axin (Fig. 4A) . Unexpectedly, Axin mutant D-2 lacking its DIX domain still could readily coimmunoprecipitate with Ccd1; and mutant D-3, that lacked amino acids 600 -700 but had an intact DIX domain, failed to bind Ccd1 (Fig. 4B) . These results indicate that the Ccd1 DIX domain interacts with a novel domain of Axin but not its DIX domain.
Ccd1-Axin Complex Formation Competes against MEKK1
Binding to Axin-Axin must bind to one of the two mitogenactivated protein kinase 3, MEKK1, or MEKK4, to activate JNK. Furthermore, our above results showed that DIX domain and coiled-coil domain of Ccd1 each partially attenuate MEKK1-and MEKK4-mediated JNK activation by Axin. Together with our previous observations that MEKK1 binding to Axin has been shown to be highly regulated (14), we tested whether coexpressed Ccd1 had any effect on Axin-MEKK1 complex formation in the cell. As shown in Fig. 5A , Ccd1 indeed competed against MEKK1 binding to Axin in a dose-dependent manner, although MEKK1 and Ccd1 bind to separate regions far apart in Axin. Similarly, in the presence of increasing amounts of Ccd1⌬CC, MEKK1 binding to Axin was gradually diminished (Fig. 5C ). However, Ccd1⌬DIX that could not form a complex with Axin had no effect on MEKK1 binding to Axin (Fig. 5B) , confirming that the Ccd1 DIX domain is required to abolish MEKK1-mediated JNK activation by Axin.
FIG. 2. Mechanistic analysis of Ccd1 inhibition of JNK activation by Dvl.
A, Ccd1⅐Dvl complex formation is required for Ccd1 inhibition of Dvl-mediated JNK activation. Shown on the top is a diagram of Dvl mutants with the DIX or PDZ domain deleted. The two mutants were transiently transfected into HEK293T cells together with FLAG-JNK1 in the absence or presence of Myc-Ccd1. Cells were harvested at 40 h post-transfection. After immunoprecipitation with anti-FLAG, kinase assays were performed and presented as described. B, the Ccd1⅐DIX domain cooperates with the coiled-coil domain to inhibit Dvl-mediated JNK activation. Schematic diagrams on the top depict different Ccd1 deletion mutants used in the experiments. Cells were cotransfected with 1 g of FLAG-JNK1 and 2 g of HA-Dvl, together with 2 g each of Myc-tagged Ccd1 deletions depicted in Fig. 2 . Cells were harvested at 40 h after transfection, and lysates were subjected to immunokinase assays. WT, wild-type. C, Ccd1, Dvl, and Rac can coexist in a ternary complex. Cells were transfected with 1 g of HA-Dvl2 and 1 g of FLAG-Rac, together with increasing amounts of Myc-Ccd1. After immunoprecipitation (IP) with anti-FLAG for Rac protein, immunoblotting was carried out using anti-HA, anti-Myc, and anti-FLAG to detect Dvl2, Ccd1, and Rac, respectively.
Ccd1 Depletes MEKK4 from Axin by Physical Interaction
with MEKK4 -We then investigated how Ccd1 attenuates MEKK4 activation by Axin. We first wondered whether Ccd1 could also compete against MEKK4 binding to Axin. When Myc-Axin and HA-MEKK4C were cotransfected with increasing amounts of Myc-Ccd1, no decrease in Axin association with MEKK4 was observed. The first approximation was that Ccd1 did not disrupt the Axin-MEKK4 complex. However, we most unexpectedly found that Ccd1 itself formed strong complex with MEKK4 (Fig. 6A) . To determine whether the complex formation of MEKK4, Ccd1, and Axin occurs in vivo at their physiologic levels, we carried out immunoprecipitation with untransfected HEK293T cells separately using anti-MEKK4, anti-Axin, anti-Ccd1, and rabbit control IgG, followed by im- Fig. 3A . B, a region (amino acids 600 -700) distinct from the DIX domain of Axin is required for interacting with Ccd1. Schematic diagrams on the top indicate the relative positions of deleted areas in different Axin mutants. Cells were transfected with 2 g of Myc-tagged Ccd1 together with 2 g of different Axin mutants. After transfection, Ccd1 protein in cell lysates was immunoprecipitated with anti-Myc; the immunoprecipitates were analyzed for coimmunoprecipitation of Axin proteins using anti-HA.
munoblotting to examine their copresence in the immunoprecipitates. The results showed that Axin, Ccd1, and MEKK4 were detected reciprocally in the immunoprecipitates (Fig. 6B,  upper panels) . In cells cotransfected with pSUPER-Ccd1 and MEKK4, MEKK4 coimmunoprecipitated by the Ccd1 antibody is drastically less than that from cells transfected with the empty pSUPER (Fig. 6B, second lane of the lower panels) , indicating that the antibody raised against Ccd1 is specific. To A, wild-type Ccd1, Axin, and MEKK4 form a ternary complex. HEK293T cells were cotransfected with 1 g of HA-MEKK4C and 1 g of Myc-Axin, together with increasing amounts (0, 0.5, 1.0, and 2.0 g) of Myc-Ccd1. Cells were lysed 40 h after transfection, and cell lysates were subjected to immunoprecipitation (IP) with anti-HA for MEKK4, followed by immunoblotting with anti-Myc for Axin and Ccd1, and anti-HA for MEKK4. B, Axin, Ccd1, and MEKK4 form a complex in their physiological concentrations. Upper panels, endogenous MEKK4, Axin, and Ccd1 in 293T cells were immunoprecipitated separately by using anti-MEKK4, anti-Axin, anti-Ccd1, and rabbit control IgG, followed by immunoblotting to examine their copresence in the immunoprecipitates. Lower panels, cells were cotransfected with 1 g of Myc-MEKK4 and 2 g of pSUPER-Ccd1 or pSUPER vector. Immunoprecipitation with anti-Ccd1 for endogenous Ccd1 was carried out; the amount of MEKK4 coprecipitated with Ccd1 was decreased greatly with the expression of Ccd1 siRNA. C, Ccd1 could directly coprecipitate the endogenous MEKK4, but not in cells expressing MEKK4 siRNA. Cells were transfected with 1 g of Myc-Ccd1⌬DIX together with or without 2 g of pSUPER-MEKK4. Cell lysates were subjected to immunoprecipitation with anti-MEKK4 for endogenous MEKK4. Immunoprecipitates were analyzed for coimmunoprecipitation of Ccd1 using anti-Myc. Ccd1⌬DIX defective in Axin binding was used instead of the full-length Ccd1 to indicate a direct Ccd1 association of MEKK4, but not MEKK4 bound to Axin. D, determination of the MEKK4-interacting domain in Ccd1. Cells were cotransfected with 2 g of HA-MEKK4C and 2 g each of Myc-tagged Ccd1 mutants. After immunoprecipitation using anti-HA for MEKK4, immunoblotting was carried out to detect MEKK4C with anti-HA and Ccd1 proteins with anti-Myc. WT, wild-type. E, Ccd1⌬DIX retains its ability to deplete MEKK4 from Axin. Cells were cotransfected with 1 g of HA-MEKK4C and 1 g of Myc-Axin, together with increasing amounts (0, 0.5, 1.0, 2.0 g) of Myc-Ccd1⌬DIX.
test whether Ccd1 interaction with MEKK4 is direct, we transfected Ccd1⌬DIX defective in Axin binding into HEK293T cells and used anti-MEKK4 antibody to immunoprecipitate endogenous MEKK4; Ccd1⌬DIX was coimmunoprecipitated (Fig. 6C) . We then determined the Ccd1 amino acid sequence required for MEKK4 binding. Several deletion mutants of Ccd1 were cotransfected separately with HA-MEKK4C. Coimmunoprecipitation with anti-HA was performed, showing that removal of the coiled-coil domain rendered Ccd1 incapable of forming a complex with MEKK4 (Fig. 6D) . These data indicate that Ccd1 uses its coiled-coil domain to interact with MEKK4 and the DIX domain to interact with Axin, forming a ternary complex. This explains why we did not see any apparent competition of wildtype Ccd1 against MEKK4 binding to Axin. To verify that further, we used Myc-Ccd1⌬DIX instead of wild-type Ccd1 to re-perform the competition assay. Indeed, Ccd1⌬DIX depleted Axin from MEKK4 immunoprecipitate in a dose-dependent manner (Fig. 6E ).
DISCUSSION
The DIX domain is a signaling module that is conserved in Axin/conductin, Dvl, and Ccd1. In addition to its well documented function in mediating protein-protein interactions (25, 26) , the DIX domain has been shown to target Dvl to actin stress fibers and vesicular membranes (27) , and it is indispensable for JNK activation by Axin (12) . By virtue of interaction via DIX domains, Dvl interferes with Axin-mediated JNK activation (14) . In the present study, we tested whether Ccd1 could exert an effect on JNK activation by Axin and Dvl. We found that although Ccd1 itself could not activate JNK, it drastically inhibited JNK activation both by Axin and by Dvl. In addition, we found that although Ccd1 interacts with Dvl between their DIX domains, Axin utilizes a novel domain but not its DIX domain to interact with Ccd1. Although Ccd1 inhibits Dvl-mediated JNK activation by forming a ternary complex consisting of Ccd1 and Rac-bound Dvl, Ccd1 attenuates Axin-mediated JNK activation by adopting a dual mechanism to prevent MEKK1 binding and sequester MEKK4 through physical interaction (Fig. 7) .
Dvl proteins are key multimodular factors that read signals coming from the plasma membrane and route them into the correct intracellular pathways through interaction with diverse proteins using different domains (28 -30) . As with Axin, Dvl robustly activates the JNK cascade when overexpressed, which depends on the DEP domain (13) . Genetic assays have shown that Dvl-mediated JNK cascades are critical for establishment of planar cell polarity in flies (13) . A Dvl allele containing a single amino acid mutation in the DEP domain leads to defects in cell polarity, which can be rescued by the Cterminal DEP domain. In vertebrates, Dvl was shown recently to activate JNK by forming a complex with the small GTPase Rac in a Wnt-dependent manner (18) . Depletion or inhibition of Rac function perturbs convergent extension movement and gastrulation. Apart from a requirement for Rac, little is known about the regulation of Dvl activation of the JNK pathway. Our present study shows that Ccd1 forms a dimer with Dvl through its DIX domains and that Ccd1 must utilize its DIX domain to form a complex with Dvl to inhibit Dvl-mediated JNK activation. Because dimerization is not required for Dvl to activate JNK (12) , it is unlikely that Ccd1 abolishes Dvl activation of JNK by affecting its homodimer formation, but rather that Ccd1 utilizes its DIX domain for physical association and depends on another domain to exert its inhibitory effect. Supporting this notion is the finding that Ccd1 also requires its coiledcoil domain to inhibit JNK activation by Dvl. However, it remains unclear as to how the coiled-coil domain exerts its inhibitory effect. When we tried to see whether Ccd1 association with Dvl would affect Rac binding to Dvl, we instead observed a co-complex formation among Ccd1, Dvl, and Rac, although Ccd1 does not bind directly to Rac. This raises the possibility that Ccd1 binding prevents Rac from being activated or that Ccd1 offers a physical barrier to prevent Rac from interacting with normal substrates. The exact mechanism of how Ccd1 inhibits Dvl-mediated JNK activation needs to be investigated further. Meanwhile, given that Dvl also depends on Rac for JNK activation and that MEKK4 interacts with Rac, we tested whether MEKK4 acts downstream of Dvl. However, we did not observe any inhibitory effect by overexpressing kinase-dead MEKK4 (MEKK4-KM) on Dvl-activated JNK activity (data not shown).
Interestingly, Ccd1 adopts a different approach to inhibit Axin-mediated JNK activation, in line with the different mechanisms in Axin activation of JNK. We have shown that Axin requires many elements/factors to activate JNK (12, 16, 17) . Remarkably, Axin requires not only MEKK1 or MEKK4 binding to its distinct domains, it also requires homodimer/oligomer formation through the C-terminal dimerization domain, association with small ubiquitin-related modifier-E3 ligase protein inhibitor of activated STAT via the extreme C-terminal six amino acids, and a novel X domain inside the protein phosphatase 2A binding region. Moreover, the Axin-based complex engaged in JNK activation is highly modulated by conformational changes elicited by glycogen synthase kinase-3␤ and casein kinase I␣/⑀, which prevent MEKK1 and MEKK4 binding to Axin (14) . 2 In the present study, we found that like glycogen synthase kinase-3␤ and casein kinase I␣/⑀, Ccd1 binding competes against MEKK1 binding to Axin. Unexpectedly, Ccd1 does not compete against MEKK4 binding to Axin, but rather interacts directly with MEKK4 to sequester it from association with Axin. When Ccd1⌬DIX, Axin, and MEKK4 are coexpressed, MEKK4 is found to be exclusively associated with Ccd1, indicating that Ccd1 can deplete MEKK4 and render it inaccessible to Axin. Thus, Ccd1 utilizes two strategies to abol- ish Axin activation of JNK, one to compete against MEKK1 binding, the other by physical interaction to block MEKK4 activation. It was demonstrated previously that a Ccd1 mutant designated as Ccd1⌬N lacking the N-terminal half containing the coiled-coil domain, functioned as a dominant-negative suppressor of Wnt signaling (5) . It is unclear whether this dominant-negative effect is a result of its failure to inhibit the JNK cascades mediated by the two Wnt regulators Axin and Dvl.
In sum, our current study has revealed that the DIX domain protein Ccd1 inhibits JNK activation by the two critical Wnt regulators Axin and Dvl. Most remarkable is that Ccd1 adopts different means to inhibit the two JNK cascades activated by distinct mechanisms. Although the biological function of Ccd1-mediated inhibition of JNK cascades is not immediately clear, our data have revealed a perplexing regulatory network where Axin, Dvl, and Ccd1 all play a role in the JNK cascades. 
